Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein
Koc, Sumeyye, Sen, Sedat, Terzi, Yuksel, Kizilay, Ferah, Demir, Serkan, Aksoy, Durdane Bekar, Kurtulus, Fatma, Bilge, Nuray, Idilman, Egemen, Uzunkopru, Cihat, Gungor, Serdal, Cilingir, Vedat, Ethemoglu, Ozlem, Boz, Cavit, Gumus, Haluk, Kilic, Ahmet Kasim, Kisabay, Aysin, Bir, Levent Sinan, Turan, Omer Faruk, Soysal, Aysun, Koseoglu, Mesrure, Uzuner, Gulnur Tekgol, Bayindir, Hasan, Kabay, Sibel Canbaz, Cam, Mustafa, Yayla, Vildan, Tan, Huseyin, Ozcan, Abdulcemal, Taskapioglu, Ozlem, Korkmaz, Muammer, Tamam, Yusuf, Inanc, Yilmaz, Efendi, Husnu, Kotan, Dilcan, Yetkin, Mehmet Fatih, Bilgic, Adnan Burak, Sacmaci, Hikmet, Demirci, Serpil, Celik, Yahya, Poyraz, Turan, Terzi, Murat
Background: Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited. Aims: To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG. Study Design: Multicenter, retrospective, observational study. Methods: Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz May & imath;s University's Faculty of Medicine were included in the study. Results: Of the 104 patients with anti-MOG-IgG, 56.7% were women and43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients. Conclusion: For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG.
- Dergi
- BALKAN MEDICAL JOURNAL
- Yıl
- 2024
- Cilt
- 41
- Sayı
- 4
- Sayfa
- 272-279
- ISSN
- 2146-3123
- eISSN
- 2146-3131
- DOI
- 10.4274/balkanmedj.galenos.2024.2024-1-97
- WoS UID
- WOS:001267760500006